A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.

NCT Number	NCT06568237
Lead Sponsor	Teva Branded Pharmaceutical Products R&D LLC
Conditions	Multiple System Atrophy
Enrollment	350 participants
Start Date	2024-10-02
Primary Completion	2027-09-15 (estimated)
Study Completion	2027-09-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-20